The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Spertus, John A., Birmingham, Mary C., Nassif, Michael, Damaraju, C. V., Abbate, Antonio, Butler, Javed, Lanfear, David E., Lingvay, Ildiko, Kosiborod, Mikhail N., Januzzi, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018422/
https://www.ncbi.nlm.nih.gov/pubmed/35228753
http://dx.doi.org/10.1038/s41591-022-01703-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018422/
https://www.ncbi.nlm.nih.gov/pubmed/35228753
http://dx.doi.org/10.1038/s41591-022-01703-8

Ejemplares similares